Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLEXERIL vs AMITRIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, thereby increasing their synaptic concentrations. It also blocks histamine H1, alpha-1 adrenergic, and muscarinic receptors.
Adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions (FDA-approved),Off-label: Fibromyalgia, chronic muscle spasm, tension headaches, and as a sleep aid
Major depressive disorder,Neuropathic pain,Fibromyalgia,Migraine prophylaxis,Chronic tension-type headache,Insomnia (off-label),Irritable bowel syndrome (off-label)
10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.
Adults: Initial 25 mg PO once daily at bedtime, increase by 25 mg every 3-7 days as tolerated to typical maintenance 75-150 mg/day PO divided doses or single dose at bedtime. Maximum 300 mg/day.
Terminal elimination half-life is 18 hours (range 8–37 hours) with clinical context: requires dose adjustment in hepatic impairment; steady-state reached in ~3–5 days.
Terminal elimination half-life: 15–25 hours (mean 20 h); may extend to >40 h in elderly or hepatic impairment.
Primarily hepatic via CYP3A4, CYP1A2, and CYP2D6; undergoes N-demethylation and glucuronidation. Active metabolite: norcyclobenzaprine.
Hepatic, primarily via CYP2D6 and CYP3A4, with contributions from CYP1A2 and CYP2C19. Amitriptyline is metabolized to nortriptyline (active) and other metabolites.
Primarily hepatic; approximately 50% excreted in urine as metabolites, less than 1% unchanged; 40% excreted in feces via bile.
Renal: ~70% as metabolites, <5% unchanged; fecal: ~30% via bile.
~93% bound to plasma proteins, primarily albumin.
90–95% bound to albumin and alpha-1-acid glycoprotein.
~14 L/kg (range 10–20 L/kg), indicating extensive tissue distribution.
Vd: 15–30 L/kg; extensive tissue distribution, including CNS.
Oral: ~33% due to extensive first-pass metabolism.
Oral: 30–60% due to first-pass metabolism.
No specific dosage adjustment guidelines; use with caution in renal impairment due to potential for increased side effects.
GFR 30-59 m L/min: Reduce dose by 50%. GFR 15-29 m L/min: Reduce dose by 75%. GFR <15 m L/min: Contraindicated. Hemodialysis: Not dialyzable; avoid use.
Contraindicated in hepatic impairment; Child-Pugh class A, B, C: no safe dosage established.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Use contraindicated or reduce dose by 75% with extreme caution.
Not recommended for use in children under 15 years old; safety and efficacy not established.
Children ≥12 years: Initial 25-50 mg/day PO, increase gradually to 100 mg/day in divided doses. Children 6-11 years: 1-3 mg/kg/day PO in divided doses, not to exceed 100 mg/day. Not recommended under 6 years.
Use lower starting dose (e.g., 5 mg) and titrate slowly; increased risk of sedation and anticholinergic effects. May not be well tolerated; consider alternative therapy.
Initial 10-25 mg PO at bedtime, with gradual titration. Maintenance often 50-100 mg/day. Monitor for orthostatic hypotension, falls, and anticholinergic effects.
None
Amitriptyline is not approved for use in pediatric patients. Clinical worsening and suicide risk: Monitor for clinical worsening, suicidality, or unusual changes in behavior during initial therapy. Serotonin syndrome: Serotonin syndrome has been reported with SSRIs and SNRIs.
Should not be used for longer than 2-3 weeks (acute use only),May impair mental or physical abilities required for driving or operating machinery,Central nervous system depression additive with alcohol and other CNS depressants,Anticholinergic effects: caution in patients with angle-closure glaucoma, urinary retention, or prostatic hypertrophy,Cardiovascular effects: risk of arrhythmias, especially in patients with preexisting cardiac disease (tachycardia, QT prolongation),Serotonin syndrome risk when used with MAOIs, SSRIs, SNRIs, or other serotonergic drugs,Hepatic impairment: lower doses recommended
Suicidality in children, adolescents, and young adults; serotonin syndrome; activation of mania/hypomania; seizures; angle-closure glaucoma; urinary retention; cardiovascular effects (QT prolongation, arrhythmias); impaired cognitive/motor performance.
Concurrent use of MAOIs or within 14 days of MAOI therapy,Acute recovery phase of myocardial infarction,Arrhythmias, heart block, or congestive heart failure,Hyperthyroidism
Hypersensitivity to amitriptyline or any component; concomitant use with MAOIs or within 14 days of MAOI use; recent myocardial infarction; during acute recovery phase after MI; concomitant use with cisapride.
Alcohol should be avoided due to additive CNS depression. No specific food interactions; take with or without food. Grapefruit juice does not significantly interact, but caution with high-fat meals may alter absorption slightly.
Avoid grapefruit and grapefruit juice as they may increase serum levels of amitriptyline. Limit tyramine-rich foods (aged cheeses, cured meats, fermented products) if taking MAOIs concurrently (contraindicated). Alcohol consumption may enhance sedative effects and is not recommended. High-fat meals may delay absorption but do not significantly alter overall exposure.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. Second trimester: no known risk. Third trimester: potential for neonatal adverse effects such as respiratory depression and withdrawal if used near term.
First trimester: Possible increased risk of cardiovascular malformations (OR ~1.2-1.5). Second/third trimester: Risk of neonatal withdrawal syndrome (irritability, feeding difficulties) and direct toxic effects (tachycardia, urinary retention). Late third trimester: Possible persistent pulmonary hypertension of the newborn (PPHN) with SSRI-like effects, though data limited for tricyclics.
Excreted in breast milk in small amounts (M/P ratio not established). Clinical relevance uncertain; however, due to potential for adverse effects in nursing infants, caution is advised. Alternative therapies preferred, especially when nursing a premature or low-birth-weight infant.
M/P ratio approximately 1.0-1.5. Excreted in breast milk in low amounts. Infant serum levels are usually subtherapeutic but cases of drowsiness, irritability reported. Use with caution; monitor infant for sedation and feeding difficulties. American Academy of Pediatrics considers compatible with breastfeeding if infant is healthy and full-term.
No specific dosing adjustments recommended for pregnancy. Use lowest effective dose and shortest duration due to potential neonatal effects. Pharmacokinetics may be altered in pregnancy; however, no dose adjustment guidelines exist.
Due to increased plasma volume and hepatic metabolism in pregnancy, lower serum concentrations may occur. Monitor clinical response; dose adjustments may be needed but no standard guidelines. Use lowest effective dose. Taper if discontinuing to avoid withdrawal.
Flexeril (cyclobenzaprine) is structurally related to tricyclic antidepressants (TCAs) and shares similar anticholinergic and sedative properties. It should not be used longer than 2-3 weeks due to lack of evidence for efficacy beyond that duration. Avoid in patients with hyperthyroidism, heart block, or recent MI. Concomitant use with MAOIs can cause hypertensive crisis. Onset of muscle relaxation is delayed; therapeutic effect may not be apparent until after 2-4 days. Sedation is the most common side effect and can be used to aid sleep.
For neuropathic pain, start at 10-25 mg at bedtime; titrate slowly to reduce sedative effects. Monitor QTc interval at baseline and with dose increases, especially in patients with cardiac risk factors. Anticholinergic effects (dry mouth, constipation) are common; consider prophylactic stool softeners. Avoid abrupt discontinuation; taper over 2-4 weeks to prevent withdrawal symptoms.
Do not take for longer than 3 weeks unless directed by your doctor.,This medication may cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation.,Do not stop suddenly if taken regularly; taper dose to avoid withdrawal symptoms like headache or nausea.,Inform your doctor if you have glaucoma, urinary retention, or are taking MAO inhibitors (e.g., phenelzine, tranylcypromine).,Take exactly as prescribed; do not increase dose or frequency.,May cause dry mouth; use sugar-free gum or candy for relief.
Take exactly as prescribed, usually once daily at bedtime due to drowsiness.,Do not stop suddenly; taper under doctor's guidance to avoid nausea, headache, or insomnia.,Avoid alcohol and other CNS depressants (e.g., sedatives, opioids) as they increase sedation risk.,Report any signs of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate) or cardiac symptoms (e.g., palpitations, fainting).,May cause dry mouth, constipation, blurred vision; use sugar-free gum, hydrate, and consider fiber supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLEXERIL vs AMITRIL, answered by our medical review team.
FLEXERIL is a Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that acts primarily at the brainstem, reducing tonic somatic motor activity via inhibition of descending serotonergic pathways. It is structurally related to tricyclic antidepressants and exhibits anticholinergic, sedative, and analgesic effects.. AMITRIL is a Tricyclic Antidepressant that works by Amitriptyline inhibits the reuptake of serotonin and norepinephrine, thereby increasing their synaptic concentrations. It also blocks histamine H1, alpha-1 adrenergic, and muscarinic receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLEXERIL and AMITRIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLEXERIL is: 10 mg to 15 mg orally three times a day; maximum daily dose: 30 mg.. The standard adult dose of AMITRIL is: Adults: Initial 25 mg PO once daily at bedtime, increase by 25 mg every 3-7 days as tolerated to typical maintenance 75-150 mg/day PO divided doses or single dose at bedtime. Maximum 300 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLEXERIL and AMITRIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLEXERIL is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies in pregnant women. Use only if clearly needed. First trimester: no known risk. . AMITRIL is classified as Category C. First trimester: Possible increased risk of cardiovascular malformations (OR ~1.2-1.5). Second/third trimester: Risk of neonatal withdrawal syndrome (irritability, feeding difficul. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.